Cell and gene therapies have brought transformational advancement to the care of patients with rare diseases, including, in some cases, curative treatments. These therapies are, however, not well understood by patients and their caregivers, and there is also often uncertainty in the physician and payer communities.

Health Policy weekly recaps legislative and regulatory developments and healthcare reform news that impacts the healthcare industry, particularly pharmaceutical, biotech, and device manufacturers, providers, and managed care.

Developed by a multi-disciplinary editorial board that includes health policy and reimbursement strategy experts, Health Policy Weekly delivers key insights to your inbox every week. 

Each edition of HTA Quarterly provides insights and analysis from global experts with local market expertise on key priorities and perspectives affecting HTA.

From therapeutic area spotlights to geographic reviews to critical industry topics, keep current on HTA activity around the globe with HTA Quarterly.